Search

Your search keyword '"Maria Moraleda, Jose"' showing total 5 results
Start Over Author "Maria Moraleda, Jose"
5 results on '"Maria Moraleda, Jose"'

2. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

Author

Lopez-Guillermo, Armando, Canales, Miguel Angel, Dlouhy, Ivan, Mercadal, Santiago, Briones, Javier, Martin Garcia-Sancho, Alejandro, Sancho, Juan Manuel, Maria Moraleda, Jose, Terol, Maria Jose, Salar, Antonio, Palomera, Luis, Gardella, Santiago, Jarque, Isidro, Ferrer, Secundino, Bargay, Joan, Lopez, Andres, Panizo, Carlos, Muntañola, Anna, Montalban, Carlos, Conde, Eulogio, Hernandez, Miguel T., Soler, Alfons, Garcia Marco, Jose A., Deben, Guillermo, Marin, Julian, and Tomas, Jose Francisco

Subjects
90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, Follicular lymphoma, maintenance, Follicular lymphoma, maintenance
Abstract

This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00662948). Patients in PR or CR/CR[u] after R-CHOP were randomized 1:1 to Y-90-ibritumomab-tiuxetan 0.4 mCi/kg (arm A) vs. rituximab 375 mg/m(2) every 8 weeks for 2 years (arm B). After a median follow-up of 10.55 years, 53 patients eventually progressed with a 10-year PFS of 50% vs. 56% for patients in arm A and B, respectively (HR = 1.42; p > 0.1). No significant differences were seen in OS (10-year OS 78% vs. 84.5%; HR = 1.39, p > .1). Patients receiving Y-90-ibritumomab-tiuxetan showed higher incidence of second neoplasms than those in arm B (10-year cumulative incidence 18.5 vs. 2%, respectively; p = .038). In conclusion, in FL patients responding to R-CHOP, no significant differences were found between consolidation and maintenance, although with higher late toxicity for consolidation.

Published
2022

3. Prevalencia y significado pronóstico de los marcadores mieloides en adultos con leucemia aguda linfoblástica de alto riesgo

Author

Plensa, Esther, Maria Ribera, Josep, Oriol, Albert, Bethencourt, Concepción, Parody, Ricardo, Hernández Ribas, Jesús María, José Moreno, María, del Potro, Eloy, Tormo, Mar, Rivas, Concepción, Besalduch, Joan, Ángel Sanz, Miguel, Arias, Jesús, Fernández Calvo, Javier, María Moraleda, José, Bueno, Javier, Feliu, Evarist, and José Ortega, Juan

Published
2005
Full Text
View/download PDF

4. How to Assess Risk of Progression in Multiple Myeloma Patients Achieving Complete Remission After Autologous Transplant: Sub Analysis from the GEM2012MENOS65 Phase III Clinical Trial

Author

Jimenez Ubieto, Ana, Paiva, Bruno, Martinez Lopez, Joaquin, Teresa Cedena, Maria, Puig, Noemi, Oriol, Albert, Jesus Blanchard, Maria, Martinez, Rafael, Rios, Rafael, Martin, Jesus, Sureda, Anna, Teodoro Hernandez, Miguel, La Rubia, Javier, Medina, Jose Gonzalez, Alonso Fernandez, Rafael, Krsnik, Isabel, Palomera, Luis, Maria Moraleda, Jose, Bargay, Joan, Gutierrez, Norma, Otero, Paula, Victoria Mateos, Maria, Rosinol, Laura, San Miguel, Jesus, Blade, Joan, and Juan José Lahuerta

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results